Section Arrow
BBIO.NASDAQ
- BridgeBio Pharma
Quotes are at least 15-min delayed:2026/01/08 18:34 EST
After Hours
Last
 73.99
+0.17 (+0.23%)
Bid
72.51
Ask
78
High 75.2 
Low 73 
Volume 30.57K 
Regular Hours (Closed)
Last
 73.82
-0.45 (-0.61%)
Day High 
75.49 
Prev. Close
74.27 
1-M High
78.585 
Volume 
1.75M 
Bid
72.51
Ask
78
Day Low
73.05 
Open
73.55 
1-M Low
70.35 
Market Cap 
14.31B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 75.62 
20-SMA 75.08 
50-SMA 70.32 
52-W High 78.585 
52-W Low 28.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.21/-0.14
Enterprise Value
16.04B
Balance Sheet
Book Value Per Share
-10.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.30M
Operating Revenue Per Share
0.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1033-0.0223-17.75%-- 
After Hours 0.1051 +0.0018 +1.74%
ACRVAcrivon Therapeutics1.93-1.02-34.58%-- 
After Hours 1.92 -0.01 -0.52%
VTYXVentyx Biosciences13.84+0.11+0.80%-- 
After Hours 13.79 -0.05 -0.36%
MLTXMoonLake Immunotherapeutics14.34+3.05+27.02%-- 
After Hours 14.6412 +0.3012 +2.10%
CRMDCorMedix7.51-3.66-32.77%5.05PE
After Hours 7.62 +0.11 +1.46%
Industry overview quotes are at least 15 minutes delayed
Business Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.